2026-05-08 · 2026-05 / week-1
Summary: Origin Materials is no longer an operating growth story. The board has moved to sell its PET cap technology and wind down the company, but the common stock now trades like a tiny residual claim before the proxy ...
2026-05-08 · 2026-05 / week-1
Summary: Galapagos, now approved to become Lakefront Biotherapeutics under ticker LKFT, traded at $27.73 per ADS in the latest finance quote, equal to about $1.83 billion of market value. The company reported EUR 2.98 bi...
2026-05-08 · 2026-05 / week-1
Summary: Japan Smaller Capitalization Fund traded at $11.60 on May 7, 2026, versus a $13.01 NAV, a 10.84% discount, even after the fund's conditional tender trigger was satisfied and the board said it expects to proceed ...
2026-05-08 · 2026-05 / week-1
Summary: Jet.AI is not a simple AI stock and not a clean merger spread. At $7.49 after-hours, JTAI appears to price mostly the June 11 vote and the closing-date flyExclusive stock component, while giving less credit to t...
2026-05-08 · 2026-05 / week-1
Summary: Intertek traded at 4,850p on the company investor page during this run, while EQT's third possible cash proposal stands at 5,800p per share. That is a 950p gross spread, or about 19.6%, with a hard UK Takeover C...
2026-05-08 · 2026-05 / week-1
Summary: GigCapital7 now trades like a post-redemption nuclear de-SPAC, not like a redeemable SPAC cash claim. At $6.74, the market is no longer valuing a right to roughly $10.7 of trust cash; it is valuing Hadron Energy...
2026-05-08 · 2026-05 / week-1
Summary: Genco is not trading like a cash merger spread. At $25.60, the stock sits above Diana Shipping's live $23.50 hostile tender, so the market is paying for either a higher bid, a proxy win, or a standalone drybulk ...
2026-05-08 · 2026-05 / week-1
Summary: Fermi traded at $5.12 on the latest market-data snapshot, implying about $3.22 billion of equity value for a development-stage AI power and data-center platform with no revenue-generating operations, $1.41 billi...
2026-05-08 · 2026-05 / week-1
Summary: Elme Communities is no longer a REIT story. After the January liquidating distribution, the remaining common stub trades below the company's own estimated additional distribution range, while the sale process ha...
2026-05-08 · 2026-05 / week-1
Summary: BlackRock ESG Capital Allocation Term Trust traded at $15.04 in the latest finance quote against a $15.86 NAV last reported by CEFConnect, a roughly 5.2% discount. The market is still treating ECAT like a high-d...
2026-05-08 · 2026-05 / week-1
Summary: Deltic Energy has a recommended 7.7p cash scheme from NEO NEXT+, bridge financing to replace the lapsed RockRose loan, and hard irrevocable support over 22.98% of the share count. The stock still closed at 6.50p...
2026-05-08 · 2026-05 / week-1
Summary: CyanConnode trades at 7.85p against Esyasoft's 10.44p revised possible cash offer, even after the board said it would be willing to recommend that price if a firm offer is made. The discount is not a simple merg...
2026-05-07 · 2026-05 / week-1
Summary: PN is no longer just a small solar-cable issuer with fresh financing. The public quote is pricing a tiny unlocked float, while the last two PIPE rounds and the Nanjing Cesun acquisition consideration were struck...
2026-05-07 · 2026-05 / week-1
Selected opportunity: Sensei Biotherapeutics common versus the Faeth conversion float.
2026-05-07 · 2026-05 / week-1
Summary: Rising Dragon Acquisition trades far below its last reported trust value, but the discount is not clean cash. The market is pricing the public shares as if the redemption door is either operationally jammed or t...
2026-05-07 · 2026-05 / week-1
Why this one now: The agreement was announced today, the quote still shows a discount to published NAV, and the payoff has moved from passive discount speculation to a specific cash-option mechanism.
2026-05-07 · 2026-05 / week-1
Summary: GNLN is trading like a distressed microcap that happens to own crypto. The harder read is that Greenlane now looks more like a public Berachain treasury: the common equity market cap is far below the marked valu...
2026-05-07 · 2026-05 / week-1
Summary: GeoVax rallied into a vaccine story while a June 17 stockholder vote sits in plain sight. The market price is now between two warrant strikes: $1.36 supply below the tape and $2.31 supply above it.
2026-05-07 · 2026-05 / week-1
Selected opportunity: FG Merger II common versus the BOXABL redemption cash right.
2026-05-07 · 2026-05 / week-1
Summary: Citius Oncology is trading almost exactly on the new $0.90 financing line. The market appears to be pricing a warrant wall, but the next real test is whether LYMPHIR launch data can turn that line from supply in...